A 53-year-old patient of schizoaffective disorder developed neuroleptic malignant syndrome (NMS) following treatment with haloperidol, clozapine and parenteral fluphenazine. He showed full recovery with immediate discontinuation of potential offenders and prompt treatment with a higher dose of bromocriptine and lorazepam along with management of aspiration pneumonia. Need for early recognition of NMS and treatment by a multidisciplinary team is discussed.
manage in the presence of serious medical comorbidities like central nervous system (CNS) infections, toxic encephalopathies, agitated delirium, heat stroke, etc. 6, 7 and associated complications, such as acute renal failure, venous thromboemboli, multiple system failure and aspiration pneumonia. 8 Therefore, it is essential to adopt a multidisciplinary management in such cases. We are reporting a case who developed NMS following addition offluphenazinetohaloperidolandclozapine.Thiscase is primarily reported to highlight the efficacy of early institution of higher dose of bromocriptine and loraz epam and need for multidisciplinary care in averting this potentially fatal condition.
CASe RepoRT
A 53yearold patient of schizoaffective disorder was admitted in psychiatry ward with acute exacerbation. His symptoms stabilized with haloperidol 10 mg/day, divalproex sodium 1000 mg/day, clozapine 400 mg/ day, trihexyphenidyl 4 mg/day and clonazepam 2 mg/day. However, in view of chronic course and poor drug compliance in the past, he was also given two injec tionsof25mgfluphenazinedecanoateeach,after3and 4 weeks of admission. He was discharged on above medicines after 4 weeks. About 12 days after discharge, the patient started worsening and was ultimately admitted under medicine with the complaints of altered consciousness, body stiffness, urinary incontinence and loss of appetite. On examination, patient appeared dehydrated; he was febrile (101.6ºF), diaphoretic, stuporose, had sialorr hea, tremulousness, marked body rigidity, positive Babinski's sign and coarse lung crepitations. His pulse rate was 126 beats/minute, respiratory rate 24 breaths/ minute and blood pressure 100/60 mm Hg. In view of history of psychiatric treatment, a presumptive diag nosis of neuroleptic induced severe extrapyramidal symptoms with aspiration pneumonia was kept along with a rider to rule out meningoencephalitis. All psycho tropics except trihexyphenidyl were discontinued, patient was cathete rized, I/V line, N/G tube feeding, cold spon ging, inputoutput charting and recording of vital parameters was advised. Cerebral spinal fluid (CSF) jpmer examination was done and broad spectrum antibiotics and diazepam (5 mg I/V slowly qid) were started. On psychiatric consultation, the author (RCS) kept a strong possibility of NMS with aspiration pneumonia and startedbromocriptine10mgbidfirstdaythen10mgtid orally and swapped diazepam with lorazepam 8 mg/day I/V dividedly.
Patient's ECG, CThead, CSF examination, urinalysis, blood and urine culture were within normal limits but chest Xray was suggestive of aspiration pneumonia. Complete blood count (CBC) showed marked leukocy tosis (WBC-23,300/cmm) with a shift to left (neutrophil count-90%). Abnormal laboratory parameters included aspartate aminotransferase 501 IU (normal 1043) and ala nine aminotransferase 521 IU (normal 1030), blood urea nitrogen-77 mg/dl (normal 2040), serum creat nine-1.7/dl (normal 0.51.5) and total CPK1997 IU/l (normal 24195). The patient's temperature normalized after 1 week butotherparameterskeptfluctuating:pulserate80to126 beats/minute, blood pressure 100/60 to 130/90 mm Hg and respiratory rate 18 to 24 breaths/minute.
Just after 2 days, patient's sensorium improved, rigi dity decreased and he started responding to verbal com mands. He cooperated for chest physiotherapy also and over the next 5 days, he became more alert and afebrile and his vital signs stabilized. He showed marked improve ment after 15 days and was shifted to psychiatry ward. He started taking orally; bromocriptine and lorazepam were gradually tapered off over next 15 days (total duration 30 days) without any recurrence of psychotic symptoms. The patient was discharged on 4 mg trihexyphenidyl/day after 3 weeks of hospital stay and was maintaining well 1 month after discharge.
DiSCuSSioN
Different types of diagnostic criteria have been proposed for diagnosing NMS; however, due to its variable presen tation, no single set of criteria is used universally.
1,9
Levenson's criteria 10 have been widely cited. It includes three major criteria; fever, rigidity and raised CPK levels and six minor criteria; altered consciousness, diaphoresis, tachypnea, tachycardia, abnormal blood pressure and leukocytosis. For the diagnosis of NMS, presence of all the three major or two major and four minor criteria need to besatisfied.Onthebasisofhistoryofexposuretoneuro leptics, clinical examination and positive Levenson's cri teria,afinaldiagnosisofNMSwithaspirationpneumonia was made in our case. Possibility of meningoencephalitis was already ruled out by a negative CSF report. All the three neuroleptics taken by this patient, i.e. haloperidol,clozapineandfluphenazineareknownto cause NMS, 1, 6, 11, 12 furthermore, propensity for NMS rises with neuroleptic polypharmacy. 13, 14 Therefore, this may be a possible reason for developing NMS in the present case. However, as NMS is most often seen with the high potency and depot neuroleptics, such as haloperidol andfluphenazine, 1, 6, 12, 15 it is more likely that these two drugs must have lead to the development of NMS in this case. In our patient, in addition to dehydration, adminis trationofanotherdepotinjectionoffluphenazinejust after7daysofthefirst,mighthavecontributedmoreor compounded the risk for NMS with haloperidol by way of massive dopa minergic receptor antagonism because, NMS is known to result from deficient compensatory mechanisms follow ing blockade of dopaminergic regula tion of muscle tone and autonomic function. Bromocriptine (2.55 mg 8 hourly per orally or by nasogastric tube) has been listed under 1st line inter vention for the treatment of moderate to severe NMS spectrumrelated symptoms. 19 It has been recommended that bromocriptine should be instituted with a starting dose of 2.5 mg 2 to 3 times a day, which can be increased to a total daily dose of 45 mg if needed. 6 In view of the severity of NMS on the very first day, we had started with bromocriptine 10 mg bid which is a relatively higher than recommended starting dose for bromocriptine and increased it to 10 mg tid on the 2nd day. Bromocriptine can worsen psychosis and hypotension and may precipi tate vomiting, and thus should be avoided in patients with risk of aspiration. Premature discontinuation of bromo criptine should be avoided as it can result in rebound symptoms in some cases. 6 Rapid development of NMS symptoms, quick res ponse and full recovery with bromocriptine which enhanced dopamine transmission and lorazepam which reduced muscle rigidity is noteworthy and is in line with similar reports. 3, 2022 Neuroleptic malignant syndrome is a potentially lethal side effect of neuroleptic drugs regardless of their duration or dose. 9 The mortality and morbidity associated withNMScanbedecreasedsignificantlyiftheoffending agents are stopped immediately; drugs like bromocriptine and lorazepam are instituted early and in high tolerable doses along with careful screening and management of complications by a multidisciplinary team.
